Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor JAMA DERMATOLOGY Chang, A. S., Kim, J., Luciano, R., Sullivan-Chang, L., Colevas, A. D. 2016; 152 (1): 106–8
View details for PubMedID 26422398